Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Published:2016-09-07 Issue:2 Volume:123 Page:294-302
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias¹,Short Nicholas J.²,Jorgensen Jeffrey L.³,Yilmaz Musa¹,Ravandi Farhad¹,Wang Sa A.³,Thomas Deborah A.¹,Khoury Joseph³,Champlin Richard E.⁴,Khouri Issa⁴,Kebriaei Partow⁴,O'Brien Susan M.⁵,Garcia-Manero Guillermo¹,Cortes Jorge E.¹,Sasaki Koji¹,Dinardo Courtney D.¹,Kadia Tapan M.¹,Jain Nitin¹,Konopleva Marina¹,Garris Rebecca¹,Kantarjian Hagop M.¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

4. Department of Stem Cell Transplantation; The University of Texas MD Anderson Cancer Center; Houston Texas

5. Chao Family Comprehensive Cancer Center; University of California Irvine; Orange California

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia;Bruggemann;Blood.,2006

2. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993;Patel;Br J Haematol.,2010

3. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial;Ribera;J Clin Oncol.,2014

4. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia;Ravandi;Br J Haematol.,2016

5. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group;Oriol;Haematologica.,2010

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

2. Recommendations for the treatment and management of adult B‐Cell acute lymphoblastic leukemia in Asia‐Pacific: Outcomes from a pilot initiative;Asia-Pacific Journal of Clinical Oncology;2023-12-26

3. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings;Indian Journal of Hematology and Blood Transfusion;2023-03-30

5. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis;Therapeutic Advances in Hematology;2023-01